Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative

This page shows the latest neurodegenerative news and features for those working in and with pharma, biotech and healthcare.

Redmile and Google help Evox raise £35.5m for exosome pipeline

Redmile and Google help Evox raise £35.5m for exosome pipeline

Evox’lead programme is an exosome-based drug to deliver proteins deficient in Niemann-Pick disease type C, a rare inherited neurodegenerative disease caused by an accumulation of lipids in the

Latest news

More from news
Approximately 7 fully matching, plus 116 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound KPT-350 (IND ready) other assets for neurological and neurodegenerative conditions.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    These deals were mainly early stage deals in the areas of gastroenterology, neurodegenerative diseases and an $830m ($40m upfront) deal with Mersana for rights outside North America to a phase 1

  • Deal Watch December 2016 Deal Watch December 2016

    320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases.

  • Deal Watch November 2016 Deal Watch November 2016

    equity investment, 2 year collaboration. 145. Chase Pharmaceuticals/ Allergan. fixed dose combinations for Alzheimer's and other neurodegenerative diseases inc CPC-201 (donepezil).

  • Deal Watch February 2016 Deal Watch February 2016

    The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Biogen appoints executive VP, corporate development Biogen appoints executive VP, corporate development

    I'm excited to work with Biogen's innovative and talented team as we work to expand the company's portfolio of therapies for people living with serious neurodegenerative diseases.”.

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    Prevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition of Francois Nader. ... The Prevail team has already made

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Asceneuron appoints chief medical officer. Novartis’ Michael Ryan joins the neurodegenerative diseases specialist. ... He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    Prof De Strooper is currently a professor of molecular medicine at the University of Leuven and leads its laboratory for the research of neurodegenerative diseases.

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Dr Mikael Dolsten, president of worldwide research and development at Pfizer, said: “ Dr Isacson's deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer's and

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Alzheimer's and Brain Awareness Month

    AD is a neurodegenerative disease, meaning that its symptoms are generally mild at the start, but become progressively worse over time, eventually interfering with the everyday life of those affected.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics